Latest news

Thumbnail image for Roche’s skin cancer drug Erivedge pulled from CDF

Roche’s skin cancer drug Erivedge pulled from CDF

Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer.

13th October 2017

Thumbnail image for ABPI, BLF launch lung disease taskforce

ABPI, BLF launch lung disease taskforce

The Association of the British Pharmaceutical Industry (ABPI) and the British Lung Foundation (BLF) have launched a new working party tasked with producing a new national five-year prevention, diagnosis and treatment plan for lung health.

13th October 2017

Thumbnail image for NICE backing for Bayer’s Stivarga in GIST

NICE backing for Bayer’s Stivarga in GIST

Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).

12th October 2017

Thumbnail image for Health and care leaders fear winter will cripple NHS

Health and care leaders fear winter will cripple NHS

More than 90 percent of health and care leaders across England say they are “concerned” about their organisation's ability to cope with demand this winter, with the majority (63 percent) citing “extreme” concern.

12th October 2017

Thumbnail image for Pfizer considers sale of consumer health division

Pfizer considers sale of consumer health division

Pfizer says it is considering the future of its massive consumer health division, with options including a full or partial separation of the business through a spin-off, sale or other transaction, or keeping hold of the unit.

11th October 2017

Thumbnail image for Akcea’s rare lipid disorder drug wins PIM status

Akcea’s rare lipid disorder drug wins PIM status

Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.

10th October 2017

Thumbnail image for AZ’ lung cancer drug Tagrisso bags breakthrough status

AZ’ lung cancer drug Tagrisso bags breakthrough status

AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.

10th October 2017

Previous  --   17 18 19 20 21 22 23 24 25 26   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download